£95.63

Springer Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants: New Vistas In Parkinson's Disease Therapy: 1 (Current Topics in Neurotoxicity, 1)

Price data last checked 91 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£96 today · cheaper than every other day in the last 24 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 640 days • 640 data points (No recent data available)

Historical
Generating forecast...
£108.10 £94.38 £97.38 £100.37 £103.36 £106.35 £109.35 09 June 2024 15 November 2024 24 April 2025 01 October 2025 10 March 2026

Price Distribution

Price distribution over 640 days • 5 price levels

Days at Price
Current Price
34 days · current 83 days 395 days 117 days 11 days 0 99 198 296 395 £96 £101 £102 £103 £108 Days at Price

Price Analysis

Most common price: £102 (395 days, 61.7%)

Price range: £96 - £108

Price levels: 5 different prices over 640 days

Description

       The specific topic, “Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants – New Perspectives In Parkinson`S Disease Therapy,” was chosen in light of accumulating neurobiological evidence indicating that, in addition to exogenous neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP]), endogenous compounds may play an important role in the most common neurodegenerative disorders (e.g., Parkinson`s disease). Two groups of amine related compounds, which appeared chemically like MPTP, were detected in human brain and cerebrospinal fluid (CSF): ß-carbolines (BCs) and tetrahydroisoquinolines  (TIQs). These are heterocyclic compounds formed endogenously from phenylalanine/tyrosine (TIQs) and tryptophan, tryptamine, and 5-hydroxytryptamine (BCs), respectively and exert a wide spectrum of psychopharmacological and behavioral effects. The TIQs and BCs may bind to their own high affinity sites on neuronal membranes associated with or located close to the receptors of neurotransmitters. Research on TIQs and BCs is stimulated also by their possible role in pathological conditions, especially parkinsonism and alcoholism. Recently, clinical interest has been spurred by their role as neuroprotective, and even neurorestorative, anticonvulsant and antiaddictive, substances.             In this book we are going to summarize, for the first time, the results from behavioral, neurochemical and molecular experiments, which demonstrate a wide spectrum of TIQs and BCs effects - from their rather mild neurotoxic actions to the important neuroprotective and antiaddictive properties. Additionally, the recent results of experimental studies in vivo have allowed a much better understanding and simultaneous comparison of the neurochemical and molecular mechanisms underlying the neuroprotective and neurotoxic actions of endogenous TIQs and BCs and have pointed to the possibility of their therapeutic applications in neurodegenerative diseases such as Parkinson's disease. From the Back Cover This book summarizes, for the first time, the results from behavioral, neurochemical and molecular experiments, which demonstrate a wide spectrum of tetrahydroisoquinolines (TIQs) and beta-carbolines (BCs) effects - from their rather mild neurotoxic actions to the important neuroprotective and antiaddictive properties.  Additionally, the recent results of experimental studies in vivo have allowed a much better understanding and simultaneous comparison of the neurochemical and molecular mechanisms underlying the neuroprotective and neurotoxic actions of endogenous TIQs and BCs and have pointed to the possibility of their therapeutic applications in neurodegenerative diseases such as Parkinson's disease. The specific topic, Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants – New Perspectives In Parkinson's Disease Therapy, was chosen in light of accumulating neurobiological evidence indicating that, in addition to exogenous neurotoxins (e.g., 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine [MPTP]), endogenous compounds may play an important role in the most common neurodegenerative disorders (e.g., Parkinson's disease). Two groups of amine related compounds, which appeared chemically like MPTP, were detected in human brain and cerebrospinal fluid (CSF): BCs and TIQs. These are heterocyclic compounds formed endogenously from phenylalanine/tyrosine (TIQs) and tryptophan, tryptamine, and 5-hydroxytryptamine (BCs), respectively, and exert a wide spectrum of psychopharmacological and behavioral effects. The TIQs and BCs may bind to their own high affinity sites on neuronal membranes associated with or located close to the receptors of neurotransmitters. Research on TIQs and BCs is stimulated also by their possible role in pathological conditions, especially parkinsonism and alcoholism. Recently, clinical interest has been spurred by their role as neuroprotective, and even neurore

Product Specifications

Format
Hardcover
Domain
Amazon UK
Release Date
06 December 2011
Listed Since
03 August 2011

Barcode

No barcode data available

Similar Products You Might Like

Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants: New Vistas In Parkinson's Disease Therapy: 1 (Current Topics in Neurotoxicity, 1)
98% match

Isoquinolines And Beta-Carbolines As Neurotoxins And Neuroprotectants: New Vistas In Parkinson's Disease Therapy: 1 (Current Topics in Neurotoxicity, 1)

Springer

£82.66 19 Dec 2025
Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders
95% match

Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders

Academic Press

£105.16 24 Feb 2026
Clinical Studies and Therapies in Parkinson's Disease: Translations from Preclinical Models
95% match

Clinical Studies and Therapies in Parkinson's Disease: Translations from Preclinical Models

Academic Press

£101.49 14 Apr 2026
Trace Amines and Neurological Disorders: Potential Mechanisms and Risk Factors
95% match

Trace Amines and Neurological Disorders: Potential Mechanisms and Risk Factors

Academic Press

£90.29 28 Mar 2026
Neurobiology of DOPA as a Neurotransmitter
94% match

Neurobiology of DOPA as a Neurotransmitter

CRC Press

£230.00 31 Jan 2026
Wiley Chemical Biology of Neurodegeneration - Molecular Approach
94% match

Wiley Chemical Biology of Neurodegeneration - Molecular Approach

Wiley

£135.00 26 Feb 2026
Neuropsychopharmacology: A Tribute to Joseph T. Coyle (Advances in Pharmacology): Volume 76
94% match

Neuropsychopharmacology: A Tribute to Joseph T. Coyle (Advances in Pharmacology): Volume 76

Academic Press

£152.67 11 Mar 2026
Excitatory Amino Acids and Second Messenger Systems: 3 (Ernst Schering Foundation Symposium Proceedings)
94% match

Excitatory Amino Acids and Second Messenger Systems: 3 (Ernst Schering Foundation Symposium Proceedings)

Springer

£76.62 23 Feb 2026
Parkinson's Disease: Molecular and Therapeutic Insights From Model Systems
94% match

Parkinson's Disease: Molecular and Therapeutic Insights From Model Systems

Academic Press

£86.99 14 Apr 2026
Advances in Neuropharmacology: Drugs and Therapeutics
94% match

Advances in Neuropharmacology: Drugs and Therapeutics

CRC Press

£76.70 17 Mar 2026
Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects (Experimental and Clinical Neuroscience)
94% match

Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects (Experimental and Clinical Neuroscience)

Humana

£164.92 07 Feb 2026
Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects (Experimental and Clinical Neuroscience)
94% match

Neuropsychopharmacology of the Trace Amines: Experimental and Clinical Aspects (Experimental and Clinical Neuroscience)

Humana

£141.86 16 Apr 2026
Parkinson’s Disease―II: Aging and Neuroendocrine Relationships: 113 (Advances in Experimental Medicine and Biology, 113)
94% match

Parkinson’s Disease―II: Aging and Neuroendocrine Relationships: 113 (Advances in Experimental Medicine and Biology, 113)

Springer

£77.74 05 Mar 2026
Sigma Receptors: Their Role in Disease and as Therapeutic Targets: 964 (Advances in Experimental Medicine and Biology, 964)
94% match

Sigma Receptors: Their Role in Disease and as Therapeutic Targets: 964 (Advances in Experimental Medicine and Biology, 964)

Springer

£127.23 30 Jan 2026
Neurotoxic Factors in Parkinson’s Disease and Related Disorders
94% match

Neurotoxic Factors in Parkinson’s Disease and Related Disorders

Springer

£107.43 01 Mar 2026
Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease
94% match

Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease

Springer

£130.25 06 Feb 2026
Psychiatry for Neurologists (Current Clinical Neurology)
94% match

Psychiatry for Neurologists (Current Clinical Neurology)

Humana

£54.38 13 Jan 2026
Parkinson's Disease and Related Disorders, Part II (Volume 84) (Handbook of Clinical Neurology, Volume 84)
94% match

Parkinson's Disease and Related Disorders, Part II (Volume 84) (Handbook of Clinical Neurology, Volume 84)

Elsevier

£220.00 12 Jan 2026
Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic (Contemporary Neuroscience)
94% match

Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic (Contemporary Neuroscience)

Humana

£150.58 30 Mar 2026
Neurobiology of the Trace Amines: Analytical, Physiological, Pharmacological, Behavioral, and Clinical Aspects: 37 (Polymer Science and Technology Series, 37)
94% match

Neurobiology of the Trace Amines: Analytical, Physiological, Pharmacological, Behavioral, and Clinical Aspects: 37 (Polymer Science and Technology Series, 37)

Humana

£148.66 08 Mar 2026
5-HT2C Receptors in the Pathophysiology of CNS Disease: 22 (The Receptors, 22)
94% match

5-HT2C Receptors in the Pathophysiology of CNS Disease: 22 (The Receptors, 22)

Humana

£145.63 10 Mar 2026
Cortico-Subcortical Dynamics in Parkinson’s Disease (Contemporary Neuroscience)
94% match

Cortico-Subcortical Dynamics in Parkinson’s Disease (Contemporary Neuroscience)

Humana

£80.09 05 Mar 2026
Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside (Volume 167) (Progress in Molecular Biology and Translational Science, Volume 167)
94% match

Molecular Basis of Neuropsychiatric Disorders: from Bench to Bedside (Volume 167) (Progress in Molecular Biology and Translational Science, Volume 167)

Academic Press

£116.56 13 Apr 2026
Monoamine Oxidase Inhibitors: Clinical Pharmacology, Benefits, & Potential Health Risks
94% match

Monoamine Oxidase Inhibitors: Clinical Pharmacology, Benefits, & Potential Health Risks

£182.99 10 Feb 2026